title: Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels.
abstract: OBJECTIVE
  L-type calcium channels (Ca((V))1.2) play an important role in cardiac contraction. Roscovitine, a cyclin-dependent kinase inhibitor and promising anticancer drug, has been shown to affect Ca((V))1.2 by inhibiting current amplitude and slowing activation. This research investigates the mechanism by which roscovitine inhibits Ca((V))1.2 channels.
  
  
  METHODS
  Ca((V))1.2 channels were transfected into HEK 293 cells, using the calcium phosphate precipitation method, and currents were measured using the whole-cell patch clamp technique.
  
  
  RESULTS
  Roscovitine slows activation at all voltages, which precludes one previously proposed mechanism. In addition, roscovitine enhances voltage-dependent, but not calcium-dependent inactivation. This enhancement resulted from both an acceleration of inactivation and a slowing of the recovery from inactivation. Internally applied roscovitine failed to affect Ca((V))1.2 currents, which supports a kinase-independent mechanism and extracellular binding site. Unlike the dihydropyridines, closed state inactivation was not affected by roscovitine. Inactivation was enhanced in a dose-dependent manner with an IC(50)=29.5+/-12 microM, which is close to that for slow activation and inhibition.
  
  
  CONCLUSIONS
  We conclude that roscovitine binds to an extracellular site on Ca((V))1.2 channels to inhibit current by both slowing activation and enhancing inactivation. Purine-based drugs could become a new option for treatment of diseases that benefit from L-channel inhibition such as cardiac arrhythmias and hypertension.
authors: Department of Anesthesiology, Penn State College of Medicine, Penn State University, Hershey, PA 17033, USA.
authors: V
authors: V
authors: Yarotskyy
authors: K S
authors: KS
authors: Elmslie
mesh_terms: D001665:Binding Sites; D020746:Calcium Channels, L-Type / Q000187:drug effects* / Q000378:metabolism; D002130:Calcium Phosphates / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002460:Cell Line; D011232:Chemical Precipitation; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D004594:Electrophysiology; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011687:Purines / Q000494:pharmacology*; D000077546:Roscovitine; D014162:Transfection
chemical_list: D020746:Calcium Channels, L-Type; D002130:Calcium Phosphates; C419385:L-type calcium channel alpha(1C); D047428:Protein Kinase Inhibitors; D011687:Purines; D000077546:Roscovitine; C020243:calcium phosphate; D018844:Cyclin-Dependent Kinases
references: J Biol Chem. 2002 Jun 7;277(23):20651-9
references: 11912204
references: Neuropharmacology. 2007 Mar;52(3):883-94
references: 17125805
references: Biophys J. 2003 Jun;84(6):3662-78
references: 12770874
references: Expert Opin Investig Drugs. 2003 Jun;12(6):955-70
references: 12783600
references: Acc Chem Res. 2003 Jun;36(6):417-25
references: 12809528
references: J Neurosci Res. 2004 Mar 15;75(6):733-41
references: 14994334
references: Leukemia. 2004 Apr;18(4):747-55
references: 14973497
references: J Clin Invest. 2004 May;113(10):1382-4
references: 15146233
references: Biophys J. 2004 Nov;87(5):3181-92
references: 15339810
references: Circ Res. 1984 Sep;55(3):336-48
references: 6088117
references: Proc Natl Acad Sci U S A. 1984 Oct;81(20):6388-92
references: 6093100
references: J Clin Invest. 1986 Nov;78(5):1185-92
references: 3771791
references: Neuron. 1990 Jul;5(1):75-80
references: 2164405
references: J Gen Physiol. 1991 Nov;98(5):987-1003
references: 1662687
references: J Gen Physiol. 1992 Mar;99(3):367-90
references: 1316936
references: Mol Pharmacol. 1993 May;43(5):820-6
references: 8388993
references: Pflugers Arch. 1993 Sep;424(5-6):538-45
references: 8255738
references: Pflugers Arch. 1993 Sep;424(5-6):552-4
references: 8255741
references: Biophys J. 2000 Apr;78(4):1906-20
references: 10733970
references: Circ Res. 2001 Oct 12;89(8):700-8
references: 11597993
references: Annu Rev Physiol. 2002;64:431-75
references: 11826275
references: J Biol Chem. 2002 Mar 1;277(9):6813-21
references: 11751866
references: J Physiol. 2002 May 1;540(Pt 3):761-70
references: 11986366
references: J Pharmacol Exp Ther. 1996 Feb;276(2):637-46
references: 8632331
references: J Biol Chem. 1996 Oct 4;271(40):24471-5
references: 8798706
references: Mol Pharmacol. 1996 Nov;50(5):1388-400
references: 8913371
references: Eur J Biochem. 1997 Jan 15;243(1-2):527-36
references: 9030781
references: Annu Rev Pharmacol Toxicol. 1997;37:361-96
references: 9131258
references: Trends Pharmacol Sci. 1998 Mar;19(3):108-15
references: 9584627
references: Am J Physiol. 1999 Jan;276(1 Pt 2):H98-H106
references: 9887022
references: J Biol Chem. 1999 Apr 2;274(14):9409-20
references: 10092621
references: Neuron. 1999 Mar;22(3):549-58
references: 10197534
references: Circ Res. 1999 May 14;84(9):989-98
references: 10325236
references: Am J Physiol. 1999 Jun;276(6 Pt 2):H2168-78
references: 10362701
references: Clin Cancer Res. 2005 Jul 1;11(13):4875-87
references: 16000586
references: Biophys J. 2005 Sep;89(3):1681-91
references: 15951378
references: J Clin Invest. 2005 Dec;115(12):3306-17
references: 16322774
references: Nature. 2006 Mar 23;440(7083):463-9
references: 16554806
references: Eur J Neurosci. 2006 Jun;23(12):3200-8
references: 16820010
references: Cell. 2006 Nov 3;127(3):591-606
references: 17081980
references: Br J Cancer. 2007 Jan 15;96(1):29-37
references: 17179992
references: Biophys J. 2007 Mar 1;92(5):1522-43
references: 17158566
references: Int J Cancer. 2002 Dec 10;102(5):463-8
references: 12432547